학술논문
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Document Type
Article
Author
Source
In: Cancer Immunology, Immunotherapy . (Cancer Immunology, Immunotherapy, January 2023, 72(1):91-99)
Subject
Language
English
ISSN
14320851
03407004
03407004